SecBot SecBot
EFFECT ·Filed May 13, 2026

BIAFW

bioAffinity Technologies, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC9999999995-26-001591
IPO/offering going effective
Actionable Insight • Neutral

The effectiveness is a procedural step enabling selling stockholders to sell into the market. Monitor for any subsequent 424B prospectus supplements or insider selling filings (Form 4) that could signal near-term selling pressure. The small market cap ($1M) means even modest share sales could impact liquidity.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d ⚠ clustered
BIAFW ▲ 0.00% at T+20d
NEUTRAL call 0.00% · α vs SPY +0.61% · entry $0.2950 → $0.2950
Next anchor: T+60d due 3mo ago
Entry = T+0 close
May 13, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.78%
$0.2950
settled 6mo ago
T+5d
0.00%
call 0.00% · α +1.16%
$0.2950
settled 5mo ago
T+20d
0.00%
call 0.00% · α +0.61%
$0.2950
settled 5mo ago
T+60d
Pending
due 3mo ago

Price Chart

Loading chart...

Executive Summary

The SEC declared effective the resale registration statement (S-1, File No. 333-295465) for bioAffinity Technologies, Inc. on May 12, 2026. This allows selling stockholders to resell up to 497,483 shares of common stock (365,603 warrant shares and 131,880 conversion shares from Series B Preferred Stock). The company receives no proceeds from the resale but may receive cash from warrant exercises.

Key Facts

  • Effectiveness date: May 12, 2026
  • Registration covers 497,483 shares of common stock for resale by selling stockholders
  • Comprised of 365,603 warrant shares and 131,880 Series B Preferred conversion shares
  • Company receives no proceeds from resale; may receive cash from warrant exercises
  • Common stock trades on Nasdaq under symbol BIAF; last reported price $2.43 on April 29, 2026

Financial Impact

Up to 497,483 shares registered for resale; at $2.43/share, potential market value ~$1.2M. No proceeds to company.

dilution

Risk Factors

  • Potential overhang from selling stockholder sales, given micro-cap liquidity
  • No company proceeds from resale; dilution without capital raise

Market Snapshot

Exchange
Nasdaq
Sector
Services-Commercial Physical & Biological Research

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001591
Document: 9999999995-26-001591-index.html9999999995-26-001591
Document: 9999999995-26-001591.txt9999999995-26-001591
7 reports for BIAFW
Performance horizon
Filters
Rows
Reports for BIAFW — sortable, filterable
TypeNow
Jun 2, 2026
20w ago
8-K
NEUTRAL ★ 2/10
$0.2950 $0.1300▼ −55.93%▼ −54.37%—
May 27, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$0.2950 $0.2950· 0.00%▲ +1.90%—
May 13, 2026
23w ago
EFFECT
NEUTRAL ★ 3/10
$0.2950 $0.2950· 0.00%▲ +0.61%—
May 12, 2026
23w ago
8-K
NEUTRAL ★ 4/10
$0.2950 $0.2950· 0.00%▲ +1.73%—
May 8, 2026
24w ago
8-K
MIXED ★ 5/10
$0.2950 $0.2950· 0.00%▼ −0.02%—
Apr 14, 2026
27w ago
8-K
NEUTRAL ★ 3/10
$0.2950 $0.2950· 0.00%▼ −6.30%—
Apr 7, 2026
28w ago
8-K
NEUTRAL ★ 3/10
$0.2950 $0.2950· 0.00%▼ −9.78%—
Showing 7 of 7

US Market Status

Market Closed — Opens in 5h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026